Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

Title	Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
Authors	David Howard, David James, Jezabel Garcia-Parra, Belen Pan-Castillo, Jenny Worthington, Nicole Williams, Zoe Coombes, Sophie Colleen Rees, Kerryn Lutchman-Singh, Lewis W. Francis, Paul Rees, Lavinia Margarit, R. Steven Conlan, Deyarina Gonzalez
Magazine	Frontiers in Oncology
Date	11/25/2022
DOI	10.3389/fonc.2022.1014280
Introduction	Ovarian cancer is one of the deadliest cancers in women, often diagnosed at a late stage due to the absence of specific symptoms. Platinum-based chemotherapy is a common treatment, but resistance frequently develops, leading to poor outcomes. This study explores the potential of cyclin dependent kinase inhibitors (CDKis), particularly dinaciclib, as a treatment for platinum-resistant ovarian cancer. Dinaciclib was tested on various ovarian cancer cell lines and primary cells, demonstrating high efficacy. Notably, its effectiveness was not diminished in platinum-resistant cells, and it acted additively with cisplatin, indicating its potential role in advanced and resistant ovarian cancer treatment.
Quote	David Howard, David James and Jezabel Garcia-Parra et al. Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer. Front Oncol. 2022. Vol. 12. DOI: 10.3389/fonc.2022.1014280
Element	Platinum (Pt)
Materials	Chemical Compounds
Industry	Pharmaceutical Industry